Bionest

Analysts’ Predictions on Top 10 Best Selling Drugs in 2024 — And Our Take

Market analyst firm Evaluate released their annual report, “EvaluatePharma World Preview 2018: Outlook to 2024,” last month. The report predicts that worldwide prescription drug sales will grow to over $1.2 trillion over the next six years. Novartis is projected to be 2024’s leading prescription drug company with $53.2 billion in overall sales, followed by Pfizer...

Bionest

Welcome to 2018! What we are watching for JPM18 and the coming year…

Now that the holidays have wound down, we look forward to catching up with many of you in person as the Bionest team and many others from across the healthcare business world descend on San Francisco next week for the three-ring circus of conferences, one-on-one meetings and social gatherings that is JPM18. Here are some...

Bionest

Chan Zuckerberg Initiative Makes First Bio Research Awards

Last fall, the Chan Zuckerberg Initiative announced plans to invest $3 billion over 10 years in scientific efforts with an ambitious long-range aim to “cure, prevent or manage” all diseases. As a first part of that effort, they directed $600 million towards the establishment of the CZ Biohub in San Francisco’s Mission Bay neighborhood. This...

Bionest

No Matter What You Think of the U.S. Election Outcome…

By Alain J. Gilbert, Co-Chair, Bionest Partners   The U.S. Presidential election is over. No matter how you personally feel about the outcome, the fact of Donald Trump’s election is likely to be positive for the healthcare industry and biopharma. The reason: the issue of new drug pricing is not going to be a top...

Bionest

Data Is Key to Forming Immunotherapy Partnerships

We were pleased to participate in a “State of the Industry” panel on immuno-oncology at the 2015 BIO Investor Forum in October. The lively discussion included other participants from across the industry and investing world, including the licensing office of Merck & Co. and Baxter’s corporate venture arm, Baxalta, as well as small biotech company...